Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Eli Lilly & Co.’s stock was on pace for its worst day in about three years Thursday as investors fretted about intensifying competition among obesity-drug developers. Lilly’s stock LLY was ...

Amgen (AMGN) and Pfizer (PFE) could soon be snacking on Novo Nordisk (NVO) and Eli Lilly's (LLY) lunch in the anti-obesity market, says Morningstar. Read more here.

Eli Lilly's anti-obesity drug Zepbound (tirzepatide) receives approval in the US and recommended approval in the EU. The SELECT study data shows that semaglutide 2.4 mg reduces major adverse ...

While this adds competition to a market currently controlled by Eli Lilly LLY-2.84 % decrease; red down pointing triangle and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy ...

Chugai Pharmaceutical Co. Ltd. (OTC:CHGCY) believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s (NYSE:LLY) oral obesity pill, orforglipron. Roche Holdings AG (OTC ...

Eli Lilly’s daily anti-obesity pill orforglipron appears to be as good at spurring weight loss and lowering blood sugar in diabetes patients as popular injectable GLP-1 drugs like Ozempic, ...

CHGCY believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s LLY oral obesity pill, orforglipron. Roche Holdings AG RHHBY is a major shareholder of Chugai, a Japanese ...